The filing is a routine insider intent-to-sell notice. The officer's holdings and the sale size relative to market cap are small. Monitor for actual execution on Form 4, but no material market impact is expected.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $542.62entry
- T+1 · 4d ago −0.74%α −0.38% · $538.60
- T+2 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Charles F. Wagner Jr., an officer of Vertex Pharmaceuticals, filed a Form 144 notice of intent to sell 15,286 shares of common stock, with an estimated market value of approximately $8.37 million based on the filing. The shares were acquired through ESPP purchases and restricted stock vesting between 2023 and 2025. The sale is scheduled for November 12, 2026.
Key Facts
- Charles F. Wagner Jr., an officer of Vertex Pharmaceuticals, filed a Form 144 on November 12, 2026.
- The filing indicates intent to sell 15,286 shares of common stock.
- Estimated aggregate market value of the proposed sale is $8,374,740.82.
- Shares were acquired through ESPP purchases and restricted stock vesting between November 2023 and May 2025.
- The proposed sale date is November 12, 2026.
- The sale represents approximately 0.006% of Vertex's $138.9B market cap.
Financial Impact
Proposed sale of 15,286 shares valued at approximately $8.37 million, representing a small fraction of the company's $138.9B market cap.
Risk Factors
- Insider sale may signal personal liquidity needs rather than negative outlook, but the small size limits concern.
- The sale is not yet executed; the insider may choose not to sell.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-007958 |
| Document: 0001959173-26-007958-index.html | 0001959173-26-007958 |
| Document: 0001959173-26-007958.txt | 0001959173-26-007958 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Viewing Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers